Immunotherapy Plus Targeted Drug for Advanced Liver Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (sintilimab, an immunotherapy, and lenvatinib, a targeted therapy) followed by local treatments to try to cure advanced liver cancer that has spread to a few other parts of the body. The goal is to shrink the cancer enough that surgery or radiation can remove it completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Confirmed hepatocellular carcinoma (liver cancer) with 1–5 tumors in other organs (but no more than 2 different organ sites)
- Never received systemic (whole-body) cancer treatment before
- Good overall health (ECOG score 0–1, meaning you can do most normal activities)
- Adequate liver, kidney, and blood function based on lab tests
- Your doctor believes you could potentially have surgery or radiation after the drugs shrink the cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.